Fuyuan Pharmaceuticals (601089.SH) has received approval for the marketing application of the chemical raw material drug Alsimosil.

Zhijing Finance News App, Fuyuan Pharmaceuticals (601089.SH) announced that recently, the company received the "Chemical Raw Material Drug Market Approval Notification Letter" approved and issued by the National Medical Products Administration for the raw material drug of atorvastatin. Atorvastatin can be used as an alternative therapy or adjunct therapy to lower triglyceride levels in patients for whom other treatments (such as statins or fibrates) are not sufficient.